T cells

[Scientific Reports] Scientists demonstrated that YIV-906 plus anti-PD1 could eradicate all Hepa 1–6 tumors in all tumor bearing mice. YIV-906 was found to have multiple mechanisms of action to enhance adaptive and innate immunity.

[Lancet] Scientists assessed the safety and clinical activity of ciltacabtagene autoleucel, a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis.

[Molecular Therapy-Methods & Clinical Development] Injection of envelope-expressing antigen presenting cells one week post-CAR T-cell infusion also failed to stimulate CAR T-cell expansion in vivo.

[Laboratory Investigation] The proportion of Th17 cells in the spleen and the expression levels of IL-17A, IL-6, and vascular cell adhesion molecule- in mice of different ages were increased with aging.

[Nature Immunology] Scientists found that tumor-infiltrating follicular regulatory T cells were prevalent in tumor tissues of several cancer types.

[Cell] Researchers demonstrated that pharmacologic modulation of splicing via specific drug classes generated bona fide neoantigens and elicited anti-tumor immunity, augmenting checkpoint immunotherapy.